\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ with\\ darkened\\,\\ thickened\\,\\ warm\\ skin\\ over\\ right\\ breast\\.\\ \\ skin\\ dimpling\\ present\\.\\ \\ adenopathy\\ present\\ in\\ right\\ axilla\\.\ \(0\)\
\-\ left\\ breast\\ and\\ axilla\\ normal\\.\\ \\ exam\\ otherwise\\ unremarkable\\.\ \(0\)\
\-\ this\\ patient\\ was\\ treated\\ with\\ antibiotics\\ and\\ failed\\ to\\ improve\\ with\\ therapy\\.\ \(0\)\
\-\ a\\ biopsy\\ was\\ done\\ when\\ the\\ patient\\ returned\\ without\\ resolution\\ of\\ disease\\.\ \(0\)\
\-\ pathology\\:\\ biopsy\\ showed\\ dermal\\ lymphatic\\ invasion\\ by\\ tumor\\ cells\\,\\ atypical\\ mitotic\\ figures\\ and\\ pleomorphic\\ tumor\\ cells\\ consistent\\ with\\ inflammatory\\ breast\\ cancer\\.\\ \ \(0\)\
\-\ the\\ patient\\ was\\ then\\ referred\\ for\\ an\\ nih\\ treatment\\ protocol\\.\ \(0\)\
\-\ neoadjuvant\\ chemotherapy\\ protocol\\ followed\\ by\\ mastectomy\\ and\\ local\\ radiation\\ therapy\\.\ \(0\)\
\-\ ct\\ of\\ chest\\ shows\\ skin\\ thickening\\ over\\ right\\ breast\\,\\ significant\\ enlargement\\ of\\ right\\ breast\\ compared\\ to\\ left\\.\\ \\ fat\\ streaking\\ within\\ the\\ right\\ breast\\.\ \(0\)\
\-\ mri\\ of\\ thoracic\\ spine\\ shows\\ abnormal\\ signal\\ intensity\\ at\\ t4\\ and\\ t7\\ consistent\\ with\\ metastases\\.\ \(0\)\
\-\ inflammatory\\ breast\\ cancer\\,\\ metastatic\\ to\\ thoracic\\ spine\\ \\(stage\\ iv\\)\ \(0\)\
\-\ inflammatory\\ breast\\ cancer\\ metastatic\\ \\-stage\\ iv\ \(0\)\
\-\ inflammatory\\ breast\\ cancer\\,\\ locally\\ advanced\\-stage\\ iii\ \(0\)\
\-\ acute\\ mastitis\\ and\\/or\\ cellulitis\ \(0\)\
\-\ diffuse\\ inflammation\\ by\\ lymphoma\\ \ \(0\)\
\-\ advanced\\ non\\-inflammatory\\ breast\\ cancer\ \(0\)\
\-\ 55\\ y\\/o\\ woman\\ seen\\ as\\ an\\ outpatient\\ for\\ possible\\ mastitis\\.\ \(1\)\
\-\ in\\ 2004\\,\\ approximately\\ 217\\,440\\ women\\ were\\ diagnosed\\ with\\ breast\\ cancer\\ and\\ approximately\\ 40\\,580\\ died\\ from\\ it\\.\\ \\ breast\\ cancer\\ is\\ the\\ leading\\ cause\\ of\\ death\\ in\\ women\\ in\\ the\\ u\\.s\\.\\ ages\\ 45\\-55\\.\ \(0\)\
\-\ inflammatory\\ breast\\ cancer\\ is\\ rare\\,\\ consisting\\ of\\ 1\\-5\\%\\ of\\ invasive\\ breast\\ cancers\\.\\ \\ it\\ is\\ rapidly\\ progressive\\ and\\ the\\ most\\ lethal\\ form\\ of\\ locally\\ advanced\\ breast\\ cancer\\.\\ \\ it\\ is\\ characterized\\ by\\ early\\ metastatic\\ spread\\.\\ \\ in\\ fact\\,\\ up\\ to\\ 1\\/3\\ of\\ patients\\ have\\ distant\\ metastases\\ at\\ the\\ time\\ of\\ diagnosis\\.\ \(0\)\
\-\ while\\ biopsy\\ tends\\ to\\ show\\ characteristic\\ dermal\\ lymphatic\\ invasion\\ by\\ tumor\\ cells\\,\\ which\\ create\\ tumor\\ emboli\\ that\\ facilitate\\ in\\ the\\ early\\ metastatic\\ spread\\,\\ diagnosis\\ is\\ basically\\ clinical\\.\\ \\ the\\ hallmark\\ of\\ inflammatory\\ breast\\ cancer\\ is\\ the\\ classic\\ peau\\ d\\‚\\Ä\\ôorange\\ skin\\ changes\\.\\ \\ the\\ classic\\ definition\\ is\\ \\‚\\Ä\\údiffuse\\ brawny\\ induration\\ of\\ the\\ skin\\ of\\ the\\ breast\\ with\\ an\\ erysipeloid\\ edge\\,\\ usually\\ without\\ underlying\\ palpable\\ mass\\.\\‚\\Ä\\ù1\\ \\ as\\ in\\ this\\ case\\,\\ patients\\ are\\ frequently\\ misdiagnosed\\ with\\ acute\\ mastitis\\ or\\ a\\ breast\\ abscess\\,\\ especially\\ if\\ lactating\\,\\ when\\ they\\ first\\ present\\.\\ \\ \ \(0\)\
\-\ while\\ bilateral\\ mammograms\\ are\\ recommended\\ for\\ all\\ patients\\ with\\ breast\\ cancer\\,\\ in\\ these\\ patients\\ ct\\ and\\ mri\\ and\\ performed\\ to\\ look\\ for\\ distant\\ metastases\\ to\\ differentiate\\ between\\ stage\\ iii\\ and\\ stage\\ iv\\ cancers\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ breast\\:\\ 0\\.5698931558633651\ \(0\)\
\-\ cancer\\:\\ 0\\.3026313837269784\ \(0\)\
\-\ inflammatory\\:\\ 0\\.19550986086923353\ \(0\)\
\-\ stage\\:\\ 0\\.16446544204598693\ \(0\)\
\-\ mastitis\\:\\ 0\\.16320486212812244\ \(0\)\
\-\ skin\\:\\ 0\\.1536346746008193\ \(0\)\
\-\ advanced\\:\\ 0\\.11646265084324442\ \(0\)\
\-\ the\\:\\ 0\\.1071435591681144\ \(0\)\
\-\ of\\:\\ 0\\.10508126668816749\ \(0\)\
\-\ axilla\\:\\ 0\\.10029100946310725\ \(0\)\
\-\ metastases\\:\\ 0\\.10017798073217185\ \(0\)\
\-\ locally\\:\\ 0\\.09876519541900212\ \(0\)\
\-\ dermal\\:\\ 0\\.09674118544547475\ \(0\)\
\-\ cells\\:\\ 0\\.09547438843815885\ \(0\)\
\-\ lymphatic\\:\\ 0\\.09441912897274174\ \(0\)\
\-\ and\\:\\ 0\\.09388653437961798\ \(0\)\
\-\ patients\\:\\ 0\\.09294492580257256\ \(0\)\
\-\ metastatic\\:\\ 0\\.09061455395536713\ \(0\)\
\-\ cancers\\:\\ 0\\.08872714941925597\ \(0\)\
\-\ iv\\:\\ 0\\.08853922580872851\ \(0\)\
\-\ by\\:\\ 0\\.08770215314835458\ \(0\)\
\-\ biopsy\\:\\ 0\\.08685966016312863\ \(0\)\
\-\ tumor\\:\\ 0\\.08641931118732264\ \(0\)\
\-\ distant\\:\\ 0\\.08639169004025943\ \(0\)\
\-\ in\\:\\ 0\\.08220242940484129\ \(0\)\
\-\ protocol\\:\\ 0\\.08062288357352027\ \(0\)\
\-\ is\\:\\ 0\\.07918127738183964\ \(0\)\
\-\ women\\:\\ 0\\.07434303697324943\ \(0\)\
\-\ spread\\:\\ 0\\.07420956285620506\ \(0\)\
\-\ invasion\\:\\ 0\\.07368763829185207\ \(0\)\
\-\ with\\:\\ 0\\.07279203649844367\ \(0\)\
\-\ to\\:\\ 0\\.07228290202329174\ \(0\)\
\-\ iii\\:\\ 0\\.07132765881431469\ \(0\)\
\-\ 55\\:\\ 0\\.07100463042111424\ \(0\)\
\-\ right\\:\\ 0\\.0684713173823851\ \(0\)\
\-\ darkened\\:\\ 0\\.0660554312216653\ \(0\)\
\-\ erysipeloid\\:\\ 0\\.0660554312216653\ \(0\)\
\-\ present\\:\\ 0\\.0635845648139726\ \(0\)\
\-\ it\\:\\ 0\\.0634301108250936\ \(0\)\
\-\ brawny\\:\\ 0\\.06311949097648253\ \(0\)\
\-\ classic\\:\\ 0\\.0617880809615715\ \(0\)\
\-\ thoracic\\:\\ 0\\.06173184073871796\ \(0\)\
\-\ dimpling\\:\\ 0\\.06103640822179221\ \(0\)\
\-\ streaking\\:\\ 0\\.06103640822179221\ \(0\)\
\-\ basically\\:\\ 0\\.06103640822179221\ \(0\)\
\-\ peau\\:\\ 0\\.06103640822179221\ \(0\)\
\-\ early\\:\\ 0\\.05954764790430814\ \(0\)\
\-\ orange\\:\\ 0\\.05942064370924722\ \(0\)\
\-\ misdiagnosed\\:\\ 0\\.05942064370924722\ \(0\)\
\-\ lactating\\:\\ 0\\.05942064370924722\ \(0\)\
\-\ induration\\:\\ 0\\.05601738522191914\ \(0\)\
\-\ mitotic\\:\\ 0\\.0551645277314267\ \(0\)\
\-\ spine\\:\\ 0\\.054571837060036085\ \(0\)\
\-\ neoadjuvant\\:\\ 0\\.05440162070937414\ \(0\)\
\-\ lethal\\:\\ 0\\.05440162070937414\ \(0\)\
\-\ facilitate\\:\\ 0\\.05440162070937414\ \(0\)\
\-\ patient\\:\\ 0\\.0537375635855146\ \(0\)\
\-\ hallmark\\:\\ 0\\.053711487361109624\ \(0\)\
\-\ while\\:\\ 0\\.0533889889500177\ \(0\)\
\-\ approximately\\:\\ 0\\.052710991815372914\ \(0\)\
\-\ diffuse\\:\\ 0\\.05180649444536132\ \(0\)\
\-\ t7\\:\\ 0\\.051465680464191386\ \(0\)\
\-\ create\\:\\ 0\\.050559384210176354\ \(0\)\
\-\ figures\\:\\ 0\\.050145504731553624\ \(0\)\
\-\ for\\:\\ 0\\.05007671998893553\ \(0\)\
\-\ when\\:\\ 0\\.049901026791442184\ \(0\)\
\-\ shows\\:\\ 0\\.0484847356007544\ \(0\)\
\-\ tends\\:\\ 0\\.04776683319695607\ \(0\)\
\-\ therapy\\:\\ 0\\.04746461895244636\ \(0\)\
\-\ an\\:\\ 0\\.047384496479864424\ \(0\)\
\-\ warm\\:\\ 0\\.0462092289938203\ \(0\)\
\-\ mammograms\\:\\ 0\\.0462092289938203\ \(0\)\
\-\ consisting\\:\\ 0\\.045979339222172975\ \(0\)\
\-\ over\\:\\ 0\\.04593461395499581\ \(0\)\
\-\ definition\\:\\ 0\\.045540361210303276\ \(0\)\
\-\ consistent\\:\\ 0\\.04479286486008329\ \(0\)\
\-\ acute\\:\\ 0\\.04468867851730558\ \(0\)\
\-\ mastectomy\\:\\ 0\\.04383990661428789\ \(0\)\
\-\ without\\:\\ 0\\.04357350029261359\ \(0\)\
\-\ differentiate\\:\\ 0\\.04351071721913555\ \(0\)\
\-\ cellulitis\\:\\ 0\\.043351569722864296\ \(0\)\
\-\ died\\:\\ 0\\.043351569722864296\ \(0\)\
\-\ was\\:\\ 0\\.04318543701284299\ \(0\)\
\-\ diagnosis\\:\\ 0\\.04282427257588621\ \(0\)\
\-\ mri\\:\\ 0\\.04240447972854607\ \(0\)\
\-\ outpatient\\:\\ 0\\.042325889718642214\ \(0\)\
\-\ ages\\:\\ 0\\.04219054148649779\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.041799045084715526\ \(0\)\
\-\ failed\\:\\ 0\\.0416731128741737\ \(0\)\
\-\ edge\\:\\ 0\\.0416731128741737\ \(0\)\
\-\ look\\:\\ 0\\.041549333456747786\ \(0\)\
\-\ t4\\:\\ 0\\.04142763446444522\ \(0\)\
\-\ rapidly\\:\\ 0\\.04130794711810422\ \(0\)\
\-\ nih\\:\\ 0\\.041190205993947224\ \(0\)\
\-\ death\\:\\ 0\\.0405213382104302\ \(0\)\
\-\ emboli\\:\\ 0\\.0405213382104302\ \(0\)\
\-\ improve\\:\\ 0\\.04010745873180747\ \(0\)\
\-\ fact\\:\\ 0\\.039621308438495616\ \(0\)\
\-\ 2004\\:\\ 0\\.0389055736978852\ \(0\)\
\-\ returned\\:\\ 0\\.03882088361441481\ \(0\)\
\-\ characterized\\:\\ 0\\.037949339869443474\ \(0\)\
\-\ invasive\\:\\ 0\\.03758539796524744\ \(0\)\
\-\ leading\\:\\ 0\\.03671678221044622\ \(0\)\
\-\ form\\:\\ 0\\.03611302268466492\ \(0\)\
\-\ local\\:\\ 0\\.035555753974079715\ \(0\)\
\-\ thickened\\:\\ 0\\.03484128137737908\ \(0\)\
\-\ adenopathy\\:\\ 0\\.034744734352475506\ \(0\)\
\-\ frequently\\:\\ 0\\.034015472553349524\ \(0\)\
\-\ atypical\\:\\ 0\\.03388655069801212\ \(0\)\
\-\ underlying\\:\\ 0\\.03371814962911786\ \(0\)\
\-\ resolution\\:\\ 0\\.03351301070863604\ \(0\)\
\-\ compared\\:\\ 0\\.033392660244057286\ \(0\)\
\-\ characteristic\\:\\ 0\\.033392660244057286\ \(0\)\
\-\ inflammation\\:\\ 0\\.033196417349747605\ \(0\)\
\-\ as\\:\\ 0\\.03318724029072028\ \(0\)\
\-\ done\\:\\ 0\\.032856050376564194\ \(0\)\
\-\ recommended\\:\\ 0\\.032856050376564194\ \(0\)\
\-\ especially\\:\\ 0\\.032673649810293505\ \(0\)\
\-\ pathology\\:\\ 0\\.03242577016705206\ \(0\)\
\-\ enlargement\\:\\ 0\\.03166634519343978\ \(0\)\
\-\ progressive\\:\\ 0\\.03163506687442755\ \(0\)\
\-\ ct\\:\\ 0\\.03145028076863174\ \(0\)\
\-\ are\\:\\ 0\\.03134661648071691\ \(0\)\
\-\ at\\:\\ 0\\.031202721933779917\ \(0\)\
\-\ rare\\:\\ 0\\.031181416274777364\ \(0\)\
\-\ referred\\:\\ 0\\.030563598981256778\ \(0\)\
\-\ antibiotics\\:\\ 0\\.03043024494344939\ \(0\)\
\-\ diagnosed\\:\\ 0\\.029920110131381433\ \(0\)\
\-\ they\\:\\ 0\\.02951307526957617\ \(0\)\
\-\ otherwise\\:\\ 0\\.02944356190762683\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.029329169013618032\ \(0\)\
\-\ intensity\\:\\ 0\\.029329169013618032\ \(0\)\
\-\ then\\:\\ 0\\.029238938318409343\ \(0\)\
\-\ palpable\\:\\ 0\\.029018161472568783\ \(0\)\
\-\ or\\:\\ 0\\.02873843668030306\ \(0\)\
\-\ this\\:\\ 0\\.028386173714389486\ \(0\)\
\-\ left\\:\\ 0\\.028179963553416995\ \(0\)\
\-\ cause\\:\\ 0\\.028138776020510476\ \(0\)\
\-\ thickening\\:\\ 0\\.02810036256388378\ \(0\)\
\-\ possible\\:\\ 0\\.027986329977370984\ \(0\)\
\-\ followed\\:\\ 0\\.02789265571373872\ \(0\)\
\-\ first\\:\\ 0\\.02787406540932431\ \(0\)\
\-\ unremarkable\\:\\ 0\\.02769074119746375\ \(0\)\
\-\ showed\\:\\ 0\\.027511943975179858\ \(0\)\
\-\ radiation\\:\\ 0\\.027372018469469527\ \(0\)\
\-\ between\\:\\ 0\\.026837883706971315\ \(0\)\
\-\ abscess\\:\\ 0\\.026523011507965485\ \(0\)\
\-\ show\\:\\ 0\\.026221262864146118\ \(0\)\
\-\ clinical\\:\\ 0\\.026177065862684763\ \(0\)\
\-\ usually\\:\\ 0\\.026002927139296923\ \(0\)\
\-\ treated\\:\\ 0\\.02572169102928622\ \(0\)\
\-\ fat\\:\\ 0\\.025694158982458276\ \(0\)\
\-\ changes\\:\\ 0\\.024962922858213464\ \(0\)\
\-\ abnormal\\:\\ 0\\.02481539477527119\ \(0\)\
\-\ lymphoma\\:\\ 0\\.02459958980815453\ \(0\)\
\-\ all\\:\\ 0\\.024587787165619553\ \(0\)\
\-\ time\\:\\ 0\\.024482420267857005\ \(0\)\
\-\ performed\\:\\ 0\\.024436078224286773\ \(0\)\
\-\ if\\:\\ 0\\.023999138472695705\ \(0\)\
\-\ significant\\:\\ 0\\.023848504698265962\ \(0\)\
\-\ signal\\:\\ 0\\.023414539438131265\ \(0\)\
\-\ these\\:\\ 0\\.02332483660292587\ \(0\)\
\-\ bilateral\\:\\ 0\\.022198745195617126\ \(0\)\
\-\ chest\\:\\ 0\\.02180278762704226\ \(0\)\
\-\ woman\\:\\ 0\\.021511695714346423\ \(0\)\
\-\ most\\:\\ 0\\.02149628949663658\ \(0\)\
\-\ were\\:\\ 0\\.021291451501061633\ \(0\)\
\-\ exam\\:\\ 0\\.0207928771067422\ \(0\)\
\-\ case\\:\\ 0\\.020751102454765066\ \(0\)\
\-\ have\\:\\ 0\\.0206340332066049\ \(0\)\
\-\ up\\:\\ 0\\.0204319479159383\ \(0\)\
\-\ treatment\\:\\ 0\\.019675686988516638\ \(0\)\
\-\ seen\\:\\ 0\\.019445984226505095\ \(0\)\
\-\ within\\:\\ 0\\.01902373560227885\ \(0\)\
\-\ which\\:\\ 0\\.01878172170382253\ \(0\)\
\-\ that\\:\\ 0\\.01792475155654834\ \(0\)\
\-\ disease\\:\\ 0\\.01733830445883973\ \(0\)\
\-\ normal\\:\\ 0\\.016864489204511522\ \(0\)\
\-\ from\\:\\ 0\\.016404531297676994\ \(0\)\
